Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04479709 · ClinicalTrials.gov registry record

The Urinary Microbiome in Patients Receiving Intradetrusor Botox Injections

A clinical trial, sponsored by MetroHealth Medical Center.

Completed
Registry status
60
Enrollment target

NCT04479709 is a clinical trial that has completed, run by MetroHealth Medical Center. The registered enrollment target is 60 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04479709 has completed, sponsored by MetroHealth Medical Center.

COMPLETED
Registry status
60 participants
Enrollment target

Study Summary

An altered urinary microbiome (UM) may explain the symptoms in overactive bladder (OAB) patients who were previously considered to have "idiopathic" OAB. To date, most research on the relationship between OAB and the UM has focused on differentiating between the UM of a normal bladder and that of an OAB bladder. There is currently a paucity of data on the way that OAB therapy impacts the UM. One of the few studies to evaluate the UM pre- and post-OAB treatment focused on how management with solifenacin affected the UM, but no studies have evaluated how intravesical onabotulinumtoxin A injections (IOI) affects the UM. Understanding IOI's impact on the UM is particularly interesting because despite both anticholinergics and IOI exerting antimuscarinic affects on the bladder, IOI is often successful when anticholinergics are not. This raises the question of what other mechanisms of action IOI may have in the bladders of OAB patients - one hypothesis is that it might stabilize the UM in those select patients who suffer from OAB due to an altered UM. The primary objective of this study is therefore to determine the UM profiles of OAB patients before and after treatment with IOI.

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2021-01-01
Est. Completion 2022-06-30

Sponsor

MetroHealth Medical Center

76 total trials

What the Registry Record Tells You About NCT04479709

The ClinicalTrials.gov registry entry for NCT04479709 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MetroHealth Medical Center, which has 76 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT04479709 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04479709 about?

NCT04479709 is a clinical study titled "The Urinary Microbiome in Patients Receiving Intradetrusor Botox Injections". An altered urinary microbiome (UM) may explain the symptoms in overactive bladder (OAB) patients who were previously considered to have "idiopathic" OAB. To date, most research on the relationship between OAB and the UM has focused on differentiating between the UM of a normal bladder and that of an...

What is the current status of trial NCT04479709?

This trial is currently completed. The enrollment target is 60 participants. The study started on 2021-01-01. Estimated completion is 2022-06-30.

Who is sponsoring clinical trial NCT04479709?

This trial is sponsored by MetroHealth Medical Center, which has 76 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.